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The drive to develop bone grafts for the filling of major gaps in the skeletal structure has led 
to a major research thrust towards developing biomaterials for bone engineering. 
Unfortunately, from a clinical perspective, the promise of bone tissue engineering which was 
so vibrant a decade ago has so far failed to deliver the anticipated results of becoming a 
routine therapeutic application in reconstructive surgery. One reason is the virtual absence of 
long-term preclinical in-vivo studies which are tantamount to robust data collection 
associated while taking tissue engineering concepts from bench to bedside. Here we describe 
the analysis of long-term bone regeneration studies in preclinical animal models, exploiting 
methods of micro- and nano analysis of biodegradable composite scaffolds. We show by 
applying a comprehensive suite of analytical techniques that a scaffold based on a slow-
degrading composite material, with an architecture consisting of large pores and large pore 
interconnections leads to long-term regeneration and remodelling of functional and highly 
organized bone. 
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Introduction 
The field of tissue engineering is embodied in the collective vision of its early pioneers 
Langer and Vacanti, whose diverse yet symbiotic research approaches as an engineer and 
surgeon, led to the commencement of this interdisciplinary field. Their seminal 1993 paper 
remains one of the most influential and cited works in the field (1). The application of the 
principles of biology and engineering to the development of functional substitutes for 
damaged tissue has seen laboratories worldwide forging impressive multi-disciplinary teams 
to focus on restoring, maintaining or improving the function of a wide range of human tissues 
(2-4). While progress has been made to deliver bench to bedside solutions (5) (Figure 1), the 
rate at which tissue engineering has seen innovations translated to the clinic has been slower 
than originally expected and the urgency for tissue-engineered products which achieve these 
ideals remains high (6-9). 
 
Tissue Engineered Constructs (TEC) 
The fundamental concept underlying tissue engineering is to combine a scaffold with living 
cells, and/or biologically active molecules to form a “tissue engineering construct” (TEC) 
which promotes the repair and/or regeneration of tissues (10, 11). The design of these 
scaffolds should consider physico-chemical properties, morphology and degradation kinetics. 
A suitable scaffold will (i) possess a porous interconnected pore network (pores & pore 
interconnections should be at least 400 microns to allow vascularization) with surface 
properties which are optimized for the attachment, migration, proliferation and differentiation 
of cell types of interest (depending on the targeted tissue) and enable flow transport of 
nutrients and metabolic waste, and (ii) be biocompatible and biodegradable with a 
controllable rate to compliment cell/tissue growth and maturation (12). External size and 
shape of the construct are of importance, particularly if the construct is customized for an 
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individual patient. Scaffold design and fabrication via additive manufacturing has advanced 
tremendously over the past few years (13). The ability to create scaffolds in a layer by layer 
manner enables a computer aided design to be directly translated from a clinical scan (i.e. a 
patient CT scan) to produce customised scaffolds to fit an anatomical defect site (14-17).  
 
Regeneration and Remodelling of TECs 
On implantation of a scaffold into a bone defect site, continuous cell and tissue remodelling is 
important for achieving stable biomechanical conditions and vascularization within the host 
site (18). Importantly, TECs should stimulate and support both the onset and the continuance 
of bone in-growth as well as subsequent remodelling and maturation by providing optimal 
stiffness and external and internal geometrical shapes. Scaffolds must provide sufficient 
initial mechanical strength and stiffness to substitute for the loss of mechanical function of 
the diseased, damaged or missing tissue and in addition must degrade at a rate which is 
compatible with new tissue in-growth and maturation (3, 10). This process is depicted 
schematically in Figure. 2, which illustrates the complex interplay of scaffold degradation 
with tissue formation and maturation. The scaffold is implanted at t=0 (A,B) and over the 
first 7 days the scaffold becomes filled with a haematoma (C), followed by the formation of 
micro capillaries via angiogenesis. After 4 weeks, formation and invasion of larger blood 
vessels combined with the onset of bone formation can be detected within the scaffold (D). 
After 3 months, newly formed woven bone can be located throughout the scaffold 
architecture and the remodelling of the woven bone to lamellar bone takes place over a period 
of 6 to 12 month (E). The relationship over time between molecular weight loss-mechanical 
properties-physical weight loss and tissue regeneration is summarized in a graphical 
illustration (F).  The mPCL-TCP scaffold starts degrading after 6 month via surface erosion 
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and is completely resorbed after 3 years. The process is documented with SEM (G) and 
schematically illustrated (I). 
 
It cannot be emphasized enough how essential it is to understand and control this scaffold 
degradation process, for successful tissue formation, remodelling, and maturation at the 
defect site. In the early days of tissue engineering, it was believed that scaffolds should 
degrade and vanish as the tissue is growing (19). Yet, tissue in-growth and maturation differs 
temporally from tissue to tissue and, furthermore, tissue in-growth does not equate to tissue 
maturation and remodelling, in other words a defect filled with immature tissue should not be 
considered “regenerated”. Hence, many scaffold-based strategies have failed in the past as the 
scaffold degradation was more rapid than tissue remodelling and/or maturation (20). 
 
Translation of Bone engineering Concept from Bench to Bedside 
Bone is accustomed to carrying major biomechanical loads, as a result nature has created 
bone to be a composite material, whose components are primarily collagen, non-collagenous 
proteins and hydroxyapatite, yet whose complex structure contains a wealth of mechanically 
relevant details. Bone can be defined as a composite material in several senses i.e. being a 
porous material, a polymer-ceramic mixture, a lamellar material and a fibre-matrix material. 
Its mechanical properties will therefore depend on each of these aspects of composition and 
structure. In general, bone displays a high intrinsic regenerative capacity following trauma or 
disease. Therefore, the majority of bone defects and fractures heal without any surgical 
intervention. Refinements in surgical techniques, implant design and postoperative care have 
significantly improved treatment outcomes of complex fractures and defects as caused by 
high energy trauma, disease, developmental deformity, revision surgery, and tumour 
resection (21-26). Extensive soft tissue damage, insufficient surgical techniques, infections, 
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and biomechanical instability can, however, lead to formation of large defects with limited 
intrinsic regenerative potential (27). These defects represent a considerable surgical 
challenge, are associated with high socio-economical costs, and highly influence patients’ 
quality of life, both private and professional.  
 
The motivation for our research and the focus on translating bone engineering concepts from 
bench to bedside is rooted in the limitations in solving the increasing, and somewhat difficult, 
orthopaedic, dental, and reconstructive surgery problems facing society, and the final clinical 
outcome for patients, may be approached from the perspective of the nature of the graft 
material with which the surgeon works. Current clinically-established therapeutic approaches 
focus on the implantation of autograft and allografts, metal devices, and ceramic-based 
implants to assist repair of bone defects; all with inherent disadvantages. These constraints 
have triggered a need for new therapeutic concepts to design and engineer unparalleled 
structural and functioning bone grafts to replace current treatments. It is within this context 
that the field of bone engineering has emerged, through the integration of engineering, life 
sciences, molecular and cell biology, stem cell biology, and surgery(28)  
 
We have spent the last decade translating a concept of bone tissue engineering based on slow 
biodegradable composite scaffolds comprising medical grade polycaprolactone (mPCL) and 
calcium phosphates (hydroxyapatite (HA),tricalcium phosphate (TCP)), from the bench to the 
bedside (29-38). After a large series of in vitro experiments we consequently performed small 
animal studies using mice, rat and rabbit models which demonstrated the ability of composite 
scaffolds in combination with growth factors such as bone morphogenic protein (BMP) or 
cells to promote bone regeneration within ectopic sites or critical sized cranial defects 
(reviewed in detail by Woodruff & Hutmacher (3)).  
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Large animal models 
When selecting a large preclinical animal model a number of factors need to be considered. 
The chosen model should clearly demonstrate close physiological and pathophysiological 
analogies with humans regarding the scientific question under investigation. Moreover, it 
must be manageable to operate and observe a multiplicity of study objects over a relatively 
short period of time (39-41). Further selection criteria include costs for acquisition and care, 
animal availability, acceptability to society, tolerance to captivity and ease of housing (42). 
 
Regeneration of a Large Bone Skull defect 
We have designed and executed a long-term, pre-clinical study (Figure 3) to regenerate 
clinically relevant critical-sized cranial defects in pigs and have successfully demonstrated 
not only extensive bone regeneration but also remodelling over a period of two years within 
these defects treated with a mPCL-TCP scaffold with and without bone marrow derived 
mesenchymal stem cells (BMSC’s). We used a suite of advanced analytical techniques to 
assess the properties of the tissue-engineered bone generated during these long-term in vivo 
studies, proposing that the onset of degradation should only occur after the regenerated tissue 
within the scaffold has remodelled at least once in the natural remodelling cycle. This 
paradigm shift is particularly relevant for higher load bearing tissues, such as bone. Original 
hypotheses in the field promoted scaffold degradation to onset immediately as new tissue 
starts to form. In contrast, we underline the importance of the scaffold remaining intact as the 
tissue matures in the scaffold pores with bulk degradation occurring later. 
 
We demonstrate that this rationale, as depicted schematically in Figure 2 leads to structural 
and functional bone regeneration in a large critical-sized skull defect model in pigs and show 
here a long-term bone engineering study which supports the theory of superior bone 
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regeneration within slowly degrading composite scaffolds. Our post explantation analysis 
techniques enable bone quantity and quality to be assessed on the macro, micro and nano-
scale. The comprehensive techniques presented here, which include microcomputed 
tomography, advanced mineralized hard-tissue resin histology, scanning electron microscopy 
and small angle x-ray scattering provides key insight into the cellular and extracellular matrix 
function and organization pertaining to long-term bone remodelling behavior within clinically 
relevant defect sites which are treated with a clinically proven tissue-engineered bone 
strategy (Figure 3 and 4).  
 
Scaffolds and the surrounding tissue were explanted after 2 years and it was observed that 
extensive bone regeneration had occurred within the defect sites containing mPCL-TCP 
scaffolds both with and without BMSC addition. The scaffolds pores were filled with 
regenerated mineralized bone (Figure. 3 c-d) with extensive bone remodelling evident around 
scaffold struts and clear evidence of surface degradation of the composite scaffold matrix 
(Figure. 3g-j). The scaffold architecture was still evident within the defect sites after 2 years 
of implantation and the pores were seen to be completely filled with tissue, identified as 
mineralized bone (Figure. 3c-j).  
Micro-computed tomography was performed to determine the bone volume fraction and bone 
mineral density and 3D rendered images were generated to demonstrate the extent of 
mineralization throughout the entire scaffold (Figure. 3d). Histological assessment (Figure. 
3e-j) using von Kossa staining with Macneal’s tetrachrome counter stain highlights the black 
mineralized tissue reflecting near complete mineralization within the scaffold pores (Figure 
3e,g,i). The slow process of surface erosion and degradation of the scaffold struts is also 
evident along with remodelling taking place within the pores (Figure. 3g-j). Goldner’s 
trichrome staining (Figure 3f,h,j) reveals striking osteocytes (white arrow heads) embedded 
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within the mineralized matrix. There is notable osteoid formation around the scaffold struts 
(black arrows) demonstrating a tissue remodelling and maturation occurring as the scaffold 
gradually degrades via surface erosion enabling new bone to progressively replace the 
mPCL-TCP scaffold itself as it slowly erodes.  
 
The calcium content of both the tissue-engineered bone and the native bone in adjoining 
regions of the skull was visualized by ESEM in backscattered electron mode (BSE) and 
small-angle X-ray scattering (SAXS) patterns were collected at certain positions in the 
specimen to ascertain mineral pattern alignment, as shown in Figure. 4, indicating that bone 
had been forming all around and in-between the scaffold struts (Figure 4b,c). The areas 
corresponding to native calvarial bone show some porosity surrounded by bone material often 
with a lower mineral content (Figure. 4d,e). This indicated high remodelling activity, since 
lower mineral content usually means younger bone. Interestingly, the bone material 
surrounding the struts of the scaffold does not have a lower mineral density A possible 
explanation could be that the pores in the native calvaria gradually decrease by new bone 
formation at the inside of the pore, while tissue-engineered bone starts to grow on the surface 
of the struts and expands from there. As a consequence, the bone material around pore spaces 
in the skull is the youngest, while around the struts of the scaffold it is the oldest compared to 
the surroundings. 
 
Regeneration of a Large Segmental Tibial Defect 
Before translating new treatment concepts based on bone tissue engineering principles into a 
clinical application in orthopaedic and trauma surgery, rigorous evaluation in adequate 
preclinical animal models is absolutely essential. . Several animal models have been 
developed over the years to verify the practicability of different research approaches in bone 
  9 
regeneration. Among these, adult sheep offer the advantage of having a comparable body 
weight, similar mineral composition of bone and similar metabolic and remodelling rates to 
patients and furthermore long bone dimensions suitable for the use of human fixation 
implants and prostheses, which is not possible in small animal studies. Thus, our group has 
established a challenging 3 cm (43) (Figure 6) and 6 cm (Figure 5) ovine segmental bone 
defect model using relatively old animals which possess the secondary osteon remodelling 
which is characteristic of human bone.  
 
Our study results show that both a 3 cm (44) and a 6 cm critical-sized bone defect can be 
regenerated by recruitment and stimulation of endogenous cells by a scaffold which contains 
relevant growth factors. The bone regenerative potential of such a well-designed TEC, which 
contain a well characterised scaffold system with bone morphogenic proteins (BMPs; a 
family of growth factors which have been shown to stimulate growth, maturation and 
regulation of bone) has been shown by our group to outperform the current “gold standard”: 
autograft after 12 month of implantation. This is substantiated by X-ray, clinical CT and 
micro CT scans, biomechanical and histological assessment. Our work also shows that a 
composite scaffold loaded with 40 Mill. bone marrow-derived mesenchymal precursor cells 
stimulate more bone formation than the scaffold alone; however it shows significant lower 
bridging score and bone volume as the scaffold/BMP group. Hence, our current studies 
(Figure 6) focus on increasing the cell implantation number and adapting scaffold design 
which allow the minimal invasive injection of cells weeks after the implantation to overcome 
the initial inflammation period 1-7 days postoperatively.  
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Summary and Outlook 
A well-engineered scaffold for bone tissue engineering which is suitable to be translated from 
the bench to the bedside combines inspired design, technical innovation and precise 
craftsmanship. Original thinking in the field endorsed scaffold degradation to occur as soon 
new tissue started to form. In contrast, we emphasise the importance of the scaffolds 
remaining intact as newly formed tissue matures within the porous and fully interconnected 
scaffold architecture and that the onset of degradation should only occur after the regenerated 
tissue has remodelled at least once in the natural remodelling cycle. The importance of long-
term preclinical animal studies followed by in depth analysis of different orders of magnitude 
from macro- to micro to nano scale, using sophisticated methods to prove the outcome of 
highly organized and functional regenerated bone is crucial to future development and 
optimization of TEC’s.  
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